Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

A clinical rating scale for progressive supranuclear palsy

Lawrence I. Golbe, Pamela Ohman‐Strickland · Brain · 2007 · 597 citations · Full text

Reliability, Kinesiology, Clinical Neurology +15

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

Kiran Yanamandra, Najla Kfoury, Hong Jiang et al. · Neuron · 2013 · 578 citations · Full text

Alzheimer's Disease, Autoimmune Disease, Medicine +9

Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes

Ian Coyle‐Gilchrist, Katrina M. Dick, Karalyn Patterson et al. · Neurology · 2016 · 526 citations · Full text

Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

Ayodeji A. Asuni, Allal Boutajangout, David Quartermain et al. · Journal of Neuroscience · 2007 · 501 citations · Full text

Transgenic Mouse Models, Tau Pathology, Immunology +22

Clinical outcomes of progressive supranuclear palsy and multiple system atrophy

S. S. O'Sullivan, Luke A. Massey, David R. Williams et al. · Brain · 2008 · 412 citations · Full text